↓ Skip to main content

Dove Medical Press

Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells

Overview of attention for article published in International Journal of Nanomedicine, November 2016
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
19 Mendeley
Title
Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells
Published in
International Journal of Nanomedicine, November 2016
DOI 10.2147/ijn.s115158
Pubmed ID
Authors

Dan Shi, Yan Liu, Ronggang Xi, Wei Zou, Lijun Wu, Zhiran Zhang, Zhongyang Liu, Chao Qu, Baoli Xu, Xiaobo Wang

Abstract

Chronic myelogenous leukemia (CML) is characterized by the t(9;22) (q34;q11)-associated Bcr-Abl fusion gene, which is an essential element of clinical diagnosis. As a traditional Chinese medicine, realgar has been widely used for the treatment of various diseases for >1,500 years. Inspired by nano-drug, realgar nanoparticles (NPs) have been prepared with an average particle size of <100 nm in a previous work. Compared with coarse realgar, the realgar NPs have higher bioavailability. As a principal constituent protein of caveolae, caveolin-1 (Cav-1) participates in regulating various cellular physiological and pathological processes including tumorigenesis and tumor development. In previous studies, it was found that realgar NPs can inhibit several types of tumor cell proliferation. However, the therapeutic effect of realgar NPs on CML has not been fully elucidated. In the present paper, it was demonstrated that realgar NPs can inhibit the proliferation of K562 cells and degrade Bcr-Abl fusion protein effectively. Both apoptosis and autophagy were activated in a dose-dependent manner in realgar NPs treated cells, and the induction of autophagy was associated with class I phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin pathway. Morphological analysis indicated that realgar NPs induced differentiation effectively in CML cells. Furthermore, it was identified that Cav-1 might play a crucial role in realgar NP therapy. In order to study the effects of Cav-1 on K562 cells during realgar NP treatment, a Cav-1 overexpression cell model was established by using transient transfection. The results indicated that Cav-1 overexpression inhibited K562 cell proliferation, promoted endogenic autophagy, and increased the sensitivity of K562 cells to realgar NPs. Therefore, the results demonstrated that realgar NPs degraded Bcr-Abl oncoprotein, while the underlying mechanism might be related to apoptosis and autophagy, and Cav-1 might be considered as a potential target for clinical comprehensive therapy of CML.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 19 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 3 16%
Student > Master 3 16%
Lecturer 2 11%
Student > Postgraduate 2 11%
Student > Ph. D. Student 2 11%
Other 3 16%
Unknown 4 21%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 4 21%
Biochemistry, Genetics and Molecular Biology 4 21%
Medicine and Dentistry 2 11%
Chemical Engineering 1 5%
Neuroscience 1 5%
Other 1 5%
Unknown 6 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 November 2016.
All research outputs
#20,655,488
of 25,371,288 outputs
Outputs from International Journal of Nanomedicine
#3,127
of 4,123 outputs
Outputs of similar age
#244,639
of 317,794 outputs
Outputs of similar age from International Journal of Nanomedicine
#78
of 94 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,123 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,794 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 94 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.